Literature DB >> 33407722

Executive function is inversely correlated with physical function: the cognitive profile of adult Spinal Muscular Atrophy (SMA).

Lucas Mix1, Olivia Schreiber-Katz2, Claudia D Wurster1, Zeljko Uzelac1, Sophia Platen1, Christina Gipperich1, Gresa Ranxha2, Gary Wieselmann2, Alma Osmanovic2, Albert C Ludolph3,4, Susanne Petri2, Dorothée Lulé1.   

Abstract

BACKGROUND: Spinal muscular atrophy (SMA) issues from mutations in the survival of motor neuron (SMN) 1 gene. Loss or reduction of the SMN protein results in progressive muscle weakness. Whether this protein deficiency also affects cortical function remains unclear. While no data on adult patients exists so far, prior studies in children with SMA indicate cognitive abilities equal or even superior to healthy controls. This may suggest a possible compensatory-neuropsychological and interactional-process. The goal of this study was to assess the cognitive profile of adult patients with SMA, with a special focus on social cognition as a potential candidate for enhanced cognitive function through compensatory processes.
METHODS: In a cross-sectional design, N = 31 adult SMA patients (types II and III) were assessed for language, verbal fluency, memory, visuospatial abilities and executive function with the Edinburgh Cognitive and Behavioural ALS Screen and for social cognition with the Reading the Mind in the Eyes Test. Physical function was evaluated using the Hammersmith Functional Motor Scale Expanded. N = 19 neurologically healthy controls were matched with patients for age, sex and years of education.
RESULTS: In none of the abovementioned cognitive domains significant differences between SMA patients and controls were found. Among patients, no differences between type II SMA and type III SMA were detected for any domain. However, a trend towards better social cognition in patients with type II SMA, compared to those with type III SMA was observed. Furthermore, a significant inverse correlation of physical function and executive function was detected: lower motor function was associated with a better executive function.
CONCLUSIONS: This study shows cognitive abilities in adult SMA in the normal range for all assessed domains. Thus, reduction of SMN protein has no obvious negative impact on cognitive function. Executive functions are identified as the only cognitive domain correlated with disease severity. Therefore, executive functions may play a role in the adaptation to physical restrictions in SMA, making them a promising target for future research.

Entities:  

Keywords:  Cognition; Cognitive adaptation; Edinburgh cognitive and behavioural ALS screen (ECAS); Executive function; Hammersmith functional motor scale expanded (HFMSE); Reading the mind in the eyes test; SMA; Social cognition; Spinal muscular atrophy

Mesh:

Year:  2021        PMID: 33407722      PMCID: PMC7789267          DOI: 10.1186/s13023-020-01661-9

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  21 in total

Review 1.  The development of embodied cognition: six lessons from babies.

Authors:  Linda Smith; Michael Gasser
Journal:  Artif Life       Date:  2005 Winter-Spring       Impact factor: 0.667

2.  Infantile muscular atrophy--a broad spectrum.

Authors:  V Dubowitz
Journal:  Clin Proc Child Hosp Dist Columbia       Date:  1967-09

3.  SMN, the product of the spinal muscular atrophy-determining gene, is expressed widely but selectively in the developing human forebrain.

Authors:  Michael Briese; Dagmar-Ulrike Richter; David B Sattelle; Norbert Ulfig
Journal:  J Comp Neurol       Date:  2006-08-10       Impact factor: 3.215

4.  Precocity of the acquisition of language and type II spinal muscular atrophy in 3-4-year-old children: a study of 12 cases.

Authors:  Christelle Bénony; Hervé Bénony
Journal:  Eur J Paediatr Neurol       Date:  2005       Impact factor: 3.140

5.  Reading ability and processing in Duchenne muscular dystrophy and spinal muscular atrophy.

Authors:  C Billard; P Gillet; M Barthez; C Hommet; P Bertrand
Journal:  Dev Med Child Neurol       Date:  1998-01       Impact factor: 5.449

6.  Another advanced test of theory of mind: evidence from very high functioning adults with autism or asperger syndrome.

Authors:  S Baron-Cohen; T Jolliffe; C Mortimore; M Robertson
Journal:  J Child Psychol Psychiatry       Date:  1997-10       Impact factor: 8.982

7.  Neuropsychological performance of children with Duchenne muscular dystrophy and spinal muscle atrophy.

Authors:  T B Whelan
Journal:  Dev Med Child Neurol       Date:  1987-04       Impact factor: 5.449

8.  Revised Hammersmith Scale for spinal muscular atrophy: A SMA specific clinical outcome assessment tool.

Authors:  Danielle Ramsey; Mariacristina Scoto; Anna Mayhew; Marion Main; Elena S Mazzone; Jacqueline Montes; Roberto de Sanctis; Sally Dunaway Young; Rachel Salazar; Allan M Glanzman; Amy Pasternak; Janet Quigley; Elizabeth Mirek; Tina Duong; Richard Gee; Matthew Civitello; Gihan Tennekoon; Marika Pane; Maria Carmela Pera; Kate Bushby; John Day; Basil T Darras; Darryl De Vivo; Richard Finkel; Eugenio Mercuri; Francesco Muntoni
Journal:  PLoS One       Date:  2017-02-21       Impact factor: 3.240

Review 9.  Self-locomotion and spatial language and spatial cognition: insights from typical and atypical development.

Authors:  Ora Oudgenoeg-Paz; James Rivière
Journal:  Front Psychol       Date:  2014-06-02

Review 10.  Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - a literature review.

Authors:  Ingrid E C Verhaart; Agata Robertson; Ian J Wilson; Annemieke Aartsma-Rus; Shona Cameron; Cynthia C Jones; Suzanne F Cook; Hanns Lochmüller
Journal:  Orphanet J Rare Dis       Date:  2017-07-04       Impact factor: 4.123

View more
  1 in total

Review 1.  Changes in Ventilatory Support Requirements of Spinal Muscular Atrophy (SMA) Patients Post Gene-Based Therapies.

Authors:  Panagiota Panagiotou; Christina Kanaka-Gantenbein; Athanasios G Kaditis
Journal:  Children (Basel)       Date:  2022-08-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.